Vetoquinol SA
Closed
SectorHealthcare
68.8 0.15
Overview
Share price change
24h
Min
67.2
Max
70
Income | 7.2M 32M |
|---|---|
Sales | 10M 268M |
P/E Sector Avg | 14.271 49.888 |
Dividend yield | 1.29 |
Profit margin | 12.043 |
Employees | 2,422 |
EBITDA | 252M 301M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +63.69% upside |
Dividend yield Sector Avg | 1.29% 2.38% |
|---|
Market Cap | -115M 820M |
|---|---|
Previous open | 68.65 |
Previous close | 68.8 |
Vetoquinol SA Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Vetoquinol SA Forecast
Price Target
By TipRanks
63.69% upside
12 Months Forecast
Average 110 EUR 63.69%
High 110 EUR
Low 110 EUR
Based on 1 Wall Street analysts offering 12 month price targets forVetoquinol SA - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Vetoquinol SA
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
